Strategic News Service recently announced that Cynvenio Biosystems has been selected as a 2011 FiReStarter company, to be featured at its annual Future in Review technology conference.
The growing global incidence of breast cancer has led to an increased demand for molecular diagnostics tests that aid in diagnosing breast cancer.
Patients with this genetic variant are more likely to experience adverse drug reactions or failure of treatment.
Signal Genetics, a predictive genetic testing company focused on oncology, recently announced that it would work with pharmaceutical company Array BioPharma to advance both companies’ goals of finding biomarkers for myeloma patients.
Having a detailed overview of the patient’s life and health could aid in determining the mechanisms that caused a disease to develop.
Strategic Medicine (SMI) specializes in patient and disease stratification with the end goals of providing better healthcare and identifying unmet clinical needs.
The peer reviewed results published today in the Journal of Urology found that Aureon Laboratories’ Prostate Px+ test is twice as effective as other tools currently available at identifying which patients classified as intermediate-risk have high-risk, life-threatening cancer.